$16.67
1.04[6.65%]
At close: Apr 23
$16.70
0.0300[0.18%]
After Hours: 4:03PM EDT
Cullinan Therapeutics
(NASDAQ:CGEM)Cullinan Therapeutics Stock (NASDAQ:CGEM), Analyst Ratings, Price Targets, Predictions
Cullinan Therapeutics Inc has a consensus price target of $19.88, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from JonesTrading, BTIG, and HC Wainwright & Co. on April 17, 2024, April 17, 2024, and April 16, 2024. With an average price target of $28.33 between JonesTrading, BTIG, and HC Wainwright & Co., there's an implied 69.66% upside for Cullinan Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JonesTrading
BTIG
HC Wainwright & Co.
William Blair
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Cullinan Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | CGEM | Buy Now | Cullinan Therapeutics | $16.70 | 55.69% | JonesTrading | Soumit Roy | $22 → $26 | Maintains | Buy | Get Alert |
| 04/17/2024 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 79.64% | BTIG | Kaveri Pohlman | $20 → $30 | Maintains | Buy | Get Alert |
| 04/16/2024 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 73.65% | HC Wainwright & Co. | Edward White | $34 → $29 | Maintains | Buy | Get Alert |
| 04/15/2024 | CGEM | Buy Now | Cullinan Oncology | $16.70 | — | William Blair | Matt Phipps | — | Initiates | → Outperform | Get Alert |
| 03/14/2024 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 103.59% | HC Wainwright & Co. | Edward White | → $34 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 79.64% | Wedbush | Robert Driscoll | → $30 | Initiates | → Outperform | Get Alert |
| 10/06/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 31.74% | JonesTrading | Soumit Roy | → $22 | Initiates | → Buy | Get Alert |
| 08/11/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 103.59% | HC Wainwright & Co. | Edward White | $49 → $34 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 193.41% | HC Wainwright & Co. | Edward White | → $49 | Reiterates | → Buy | Get Alert |
| 07/07/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 193.41% | HC Wainwright & Co. | Edward White | → $49 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | — | TD Cowen | Marc Frahm | — | Initiates | → Outperform | Get Alert |
| 06/05/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 193.41% | HC Wainwright & Co. | Edward White | → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/26/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 193.41% | HC Wainwright & Co. | Edward White | → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 193.41% | HC Wainwright & Co. | Edward White | $50 → $49 | Maintains | Buy | Get Alert |
| 03/27/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 199.4% | HC Wainwright & Co. | Edward White | → $50 | Reiterates | → Buy | Get Alert |
| 03/10/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 199.4% | HC Wainwright & Co. | Edward White | → $50 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 199.4% | HC Wainwright & Co. | Edward White | → $50 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 13.77% | Morgan Stanley | Jeffrey Hung | $27 → $19 | Maintains | Overweight | Get Alert |
| 11/21/2022 | CGEM | Buy Now | Cullinan Oncology | $16.70 | 19.76% | BTIG | Kaveri Pohlman | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Cullinan Therapeutics (CGEM)?
The latest price target for Cullinan Therapeutics (NASDAQ: CGEM) was reported by JonesTrading on April 17, 2024. The analyst firm set a price target for $26.00 expecting CGEM to rise to within 12 months (a possible 55.97% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cullinan Therapeutics (CGEM)?
The latest analyst rating for Cullinan Therapeutics (NASDAQ: CGEM) was provided by JonesTrading, and Cullinan Therapeutics maintained their buy rating.
When was the last upgrade for Cullinan Therapeutics (CGEM)?
The last upgrade for Cullinan Therapeutics Inc happened on April 27, 2021 when Morgan Stanley raised their price target to N/A. Morgan Stanley previously had an equal-weight for Cullinan Therapeutics Inc.
When was the last downgrade for Cullinan Therapeutics (CGEM)?
There is no last downgrade for Cullinan Therapeutics.
When is the next analyst rating going to be posted or updated for Cullinan Therapeutics (CGEM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Therapeutics was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Cullinan Therapeutics (CGEM) correct?
While ratings are subjective and will change, the latest Cullinan Therapeutics (CGEM) rating was a maintained with a price target of $22.00 to $26.00. The current price Cullinan Therapeutics (CGEM) is trading at is $16.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.